You are here

  • Home
  • Archive
  • Volume 73, Issue Suppl 2
  • AB0746 Apremilast, an Oral Phosphodiesterase 4 Inhibitor, and the Impact of Baseline Weight and BMI on ACR20 and HAQ-DI Response: Pooled Results from 3 Phase 3, Randomized, Controlled Trials

Article metrics

Article menu
Download PDFPDF
EULAR 2014: Scientific Abstracts
Abstracts accepted for publication. Psoriatic arthritis
AB0746 Apremilast, an Oral Phosphodiesterase 4 Inhibitor, and the Impact of Baseline Weight and BMI on ACR20 and HAQ-DI Response: Pooled Results from 3 Phase 3, Randomized, Controlled Trials

 

Online download statistics by month:

Online download statistics by month: June 2014 to December 2023

AbstractFullPdf
Jun 2014500
Jul 20141200
Aug 2014400
Sep 20141100
Oct 20142304
Nov 20141801
Dec 2014401
Jan 2015100
Feb 20151000
Mar 2015901
Apr 2015100
May 20151503
Jun 2015600
Jul 2015402
Aug 2015700
Sep 20152300
Nov 20151204
Dec 2015400
Jan 2016500
Feb 2016401
Mar 2016501
Apr 20161503
May 2016904
Jun 20161102
Jul 2016500
Aug 2016501
Sep 20161301
Oct 2016401
Nov 201614023
Dec 20161301
Jan 20171101
Feb 2017901
Mar 20171200
Apr 20171500
May 2017502
Jun 2017600
Jul 2017200
Aug 20171400
Sep 2017600
Oct 2017400
Nov 2017600
Dec 20171000
Jan 2018600
Feb 2018200
Mar 20181000
Apr 2018600
May 20183403
Jun 2018200
Jul 20181000
Aug 2018801
Sep 20181401
Oct 2018400
Nov 2018200
Dec 2018600
Jan 2019400
Apr 2019400
May 2019400
Dec 2019200
Apr 20202202
Jul 2020200
Aug 20201000
Sep 20201400
Oct 2020400
Nov 2020300
Dec 2020200
Jan 2021400
Feb 2021100
Nov 2021400
Dec 20211000
Jan 2022200
Feb 2022200
Mar 2022200
May 2022400
Jun 2022200
Jul 20221600
Aug 20221001
Sep 2022400
Oct 2022400
Nov 2022600
Dec 2022400
Jan 2023400
Feb 2023200
Mar 2023400
May 2023600
Jul 2023400
Sep 2023400
Oct 2023600
Nov 20232403
Dec 2023600
Total682069